Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
about
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic reviewStarter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review.Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care CenterFactors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.Current perspectives in HIV post-exposure prophylaxis.Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.Sexual Assault and Sexually Transmitted Infections in Adults, Adolescents, and Children.Drug safety profile of integrase strand transfer inhibitors.Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015.Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.The Danish PEP Registry: Experience with the use of post-exposure prophylaxis following blood exposure to HIV from 1999-2012.PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.Reply to Tan et al.Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.Expert consensus statement on the science of HIV in the context of criminal law
P2860
Q26851448-85EDF2C0-132F-4FB8-8DB6-B62275F98E3FQ27691370-06F7D554-56B0-4276-895C-6CFF7EC62B94Q33446393-81773510-3A09-4599-BE96-3085D4876764Q33592530-F236C38F-252D-4D33-BE32-E44E77FE85ADQ34434815-1B8BCB79-269F-4DEE-9702-0D39A01F6996Q35696557-86CB7306-57F3-4CB4-A390-1A108628F64FQ35838930-778F8FF4-80FF-4E65-8E32-AFE5F581D008Q36205915-C671EE30-9612-4088-B423-E4B477DC4847Q37838425-AF49E65F-1FF1-492C-8813-AAB94A88983BQ38193524-A58F3387-D5F5-4ABB-9DBD-F76B0F2B36A6Q38620257-D22F7A9D-C49B-447D-A848-30F9F59431FBQ38812601-5B58D0F4-9B0A-4A5F-A002-53A6F2E76519Q40292568-CE948054-2032-437C-A0C6-A0A9BBA2340CQ40361364-2799BF75-F102-4D16-AA4D-FA1B8C765680Q40679634-629884F6-82B6-4897-A742-D97477161E4EQ43226795-1F99EB27-1A2B-4DBA-AA33-8BEFC1C65032Q45347873-C4FFFB55-6CC7-4ECA-B5ED-041EA3E38630Q56911620-8D0A2659-C4E6-4802-8D84-C036D7A073B5
P2860
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@en
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@nl
type
label
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@en
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@nl
prefLabel
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@en
Raltegravir-emtricitabine-teno ...... y, tolerability and adherence.
@nl
P2093
P2860
P356
P1433
P1476
Raltegravir-emtricitabine-teno ...... ty, tolerability and adherence
@en
P2093
P2860
P356
10.1111/HIV.12075
P50
P577
2013-09-06T00:00:00Z